And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We hope to spend time with a couple of our short people — busy as they are — take a nap or three, catch up on sundry tasks, and maybe do a little reading. And what about you? This may be an opportunity to see a moving picture show, visit someone special, or place bets on how much longer it may be before the U.S. government returns to normal, such as it is. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Massachusetts Gov. Charlie Baker is seeking legislative authority for MassHealth to negotiate prices directly with manufacturers of high-cost drugs that have little or no competition, CommonWealth writes. If the effort fails to produce savings, the state would put drug makers through a rate-setting process followed by regulatory and legal penalties if the company fails to charge the target price. State officials say 20 drugs recently launched or pending federal regulatory approval are expected to cost $100 million annually for the state’s Medicaid program, after expected rebates are deducted.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy